Indoor Cultivation Licence Granted to UK Startup
A UK-based startup has been granted one of the country first commercial indoor cannabis cultivation licences for medicinal supply, marking a milestone for domestic production.
A UK-based startup has received a commercial cannabis cultivation licence from the Home Office, authorising the production of cannabis for medicinal purposes at a purpose-built indoor facility in the East Midlands. The licence represents one of the first granted to a company seeking to supply licensed cannabis-based medicinal products to the UK market from domestic growing operations.
Facility Details
The facility spans approximately 3,500 square metres of controlled-environment growing space and has been constructed to EU Good Manufacturing Practice (GMP) standards, a prerequisite for supplying licensed medicinal products. The company has stated that its initial production focus will be on standardised whole-flower products for specialist pharmacy dispensing.
Significance for UK Supply Chain
- Currently, the vast majority of medical cannabis dispensed in the UK is imported from licensed producers in the Netherlands, Canada, Portugal, and Israel
- Domestic production could reduce import costs and supply chain vulnerability
- UK-grown product would carry a British-produced designation that some prescribers and patients consider advantageous for traceability
- The facility is expected to reach full production capacity within 18 months
Regulatory Pathway
The company must receive a separate manufacturer licence from the MHRA before its product can be sold into the UK pharmaceutical supply chain. This process typically takes 12 to 18 months from completed application submission.
"We believe British patients deserve access to British-grown medicine, produced to the highest standards, with full supply chain transparency."
Two further domestic cultivation licence applications are understood to be under review by the Home Office.
